JAK1 and myeloproliferative neoplasm: Arulogun et al., identified V658I missense mutation in JAK1 in a patient with myeloproliferative neoplasm.608 Additional activating mutations of JAK1, including V658F, V658L, and V658I were reported in T cell prolymphocytic leukemia and ALL.609,610